Clinical Trial Update: A Study of the Effectiveness and Safety of Risperidone to Augment SSRI Therapy in Patients With Treatment-resistant Depression [Phase 3]

View source ↗

Summary

A Phase 3 trial completed evaluating risperidone as an augmentation to SSRI therapy in treatment-resistant depression. The study assessed effectiveness and safe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Depressive Disorder
• Major Depressive Disorder

Drugs mentioned

• RISPERIDONE (RISPERIDONE)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Depressive Disorder, Depressive Disorder, Major | Phase 3 | Status: COMPLETED